Characteristics of Oncology Clinical Trials: Insights From a Systematic Analysis of ClinicalTrials.gov
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Clinical trials are essential to cancer care, and data about the current state of research in oncology are needed to develop benchmarks and set the stage for improvement. OBJECTIVE: To perform a comprehensive analysis of the national oncology clinical research portfolio. DESIGN: All interventional clinical studies registered on ClinicalTrials.gov between October 2007 and September 2010 were identified using Medical Subject Heading terms and submitted conditions. They were reviewed to validate classification, subcategorized by cancer type, and stratified by design characteristics to facilitate comparison across cancer types and with other specialties. RESULTS: Of 40 970 interventional studies registered between October 2007 and September 2010, a total of 8942 (21.8%) focused on oncology. Compared with other specialties, oncology trials were more likely to be single arm (62.3% vs 23.8%; P < .001), open label (87.8% vs 47.3%; P < .001), and nonrandomized (63.9% vs 22.7%; P < .001). There was moderate but significant correlation between number of trials conducted by cancer type and associated incidence and mortality (Spearman rank correlation coefficient, 0.56 [P = .04] and 0.77 [P = .001], respectively). More than one-third of all oncology trials were conducted solely outside North America. CONCLUSIONS AND RELEVANCE: There are significant variations between clinical trials in oncology and other diseases, as well as among trials within oncology. The differences must be better understood to improve both the impact of cancer research on clinical practice and the use of constrained resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
(1965) · Nature · doi:10.1038/205236a0 · Cited by 560
Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010
Califf, R. M. (2012) · JAMA · doi:10.1001/jama.2012.3424 · Cited by 516
Self-citationBending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351 · cited 3×
“There are limits to the registry’s completeness, because registration is required only for studies that had been initiated as of October 2007 and met the following criteria: (1) interventional study of drugs, biologics, or devices; (2) trial phase 2, 3, or 4; (3) inclusion of at least 1 US site or trial conducted unde…”
BackgroundMethodSelf-citationClinical Trial Registration — Looking Back and Moving Ahead
Laine, C., Horton, R., DeAngelis, C. D., Drazen, J. M., Frizelle, F. A., Godlee, F., Haug, C., Hébert, P. C., Kotzin, S., Marusic, A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejme078110 · Cited by 320
Scoggins, J. F., & Ramsey, S. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq291 · Cited by 318 · cited 1×
“Oncology trials were examined on 10 dimensions: (1) number of arms, (2) masking, (3) randomization, (4) phase, (5) comparator arms, (6) purpose of intervention, (7) enrollment status, (8) location of trial sites, (9) sponsor, and (10) completion status.”
BackgroundBiomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2134 · Cited by 293
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
Johnson, J. R., Ning, Y.-M., Farrell, A., Justice, R., Keegan, P., & Pazdur, R. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr062 · Cited by 212 · cited 1×
“Oncology trials were examined on 10 dimensions: (1) number of arms, (2) masking, (3) randomization, (4) phase, (5) comparator arms, (6) purpose of intervention, (7) enrollment status, (8) location of trial sites, (9) sponsor, and (10) completion status.”
BackgroundPatient-Centered Outcomes Research Institute: The Intersection of Science and Health Care
Clancy, C., & Collins, F. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001235 · Cited by 190 · cited 1×
“Oncology trials were examined on 10 dimensions: (1) number of arms, (2) masking, (3) randomization, (4) phase, (5) comparator arms, (6) purpose of intervention, (7) enrollment status, (8) location of trial sites, (9) sponsor, and (10) completion status.”
BackgroundMoving Toward Transparency of Clinical Trials
Zarin, D. A., & Tse, T. (2008) · Science · doi:10.1126/science.1153632 · Cited by 182
Tasneem, A., Aberle, L., Ananth, H., Chakraborty, S., Chiswell, K., McCourt, B. J., & Pietrobon, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033677 · Cited by 166
Self-citationSaad, E. D., Katz, A., Hoff, P. M., & Buyse, M. E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp523 · Cited by 159
Djakovic-Svajcer, K. (2002) · Medicinski pregled · doi:10.2298/mpns0202005d · Cited by 154
Ozols, R. F., Herbst, R. S., Colson, Y. L., Gralow, J. R., Bonner, J., Curran, W. J., Eisenberg, B. L., Ganz, P. A., Kramer, B. S., Kris, M. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7030 · Cited by 149
Clinical Trial Registration: Looking Back and Moving Ahead
Laine, C., Horton, R., DeAngelis, C. D., Drazen, J. M., Frizelle, F. A., Godlee, F., Haug, C., Hébert, P. C., Kotzin, S., Marusic, A., et al. (2007) · JAMA · doi:10.1001/jama.298.1.jed70037 · Cited by 135
Committee on Cancer Clinical Trials and the NCI Cooperative Group Program, Board on Health Care Services, & Institute of Medicine (2010) · National Academies Press eBooks · doi:10.17226/12879 · Cited by 134
Design and Implementation of a National Clinical Trials Registry
McCray, A. T., & Ide, N. (2000) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.2000.0070313 · Cited by 110
Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications
Abernethy, A. P., Raman, G., Balk, E. M., Hammond, J. M., Orlando, L. A., Wheeler, J. L., Lau, J., & McCrory, D. C. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-5-200903030-00107 · Cited by 96 · cited 1×
“Oncology trials were examined on 10 dimensions: (1) number of arms, (2) masking, (3) randomization, (4) phase, (5) comparator arms, (6) purpose of intervention, (7) enrollment status, (8) location of trial sites, (9) sponsor, and (10) completion status.”
BackgroundSelf-citationSchroen, A. T., Petroni, G. R., Wang, H., Thielen, M. J., Gray, R., Benedetti, J., Wang, X. F., Sargent, D. J., Wickerham, D. L., Cronin, W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1633 · Cited by 73
Phase III Clinical Trial Development: A Process of Chutes and Ladders
Dilts, D. M., Cheng, S. K., Crites, J. S., Sandler, A. B., & Doroshow, J. H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1273 · Cited by 70 · cited 2×
“There are limits to the registry’s completeness, because registration is required only for studies that had been initiated as of October 2007 and met the following criteria: (1) interventional study of drugs, biologics, or devices; (2) trial phase 2, 3, or 4; (3) inclusion of at least 1 US site or trial conducted unde…”
BackgroundSelf-citationSubramanian, J., Madadi, A. R., Desai, M. D., Williams, K., Morgensztern, D., & Govindan, R. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e76159 · Cited by 60
Health Care Reform and the Need for Comparative-Effectiveness Research
Mushlin, A. I., & Ghomrawi, H. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0912651 · Cited by 59
Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP–Sponsored Clinical Trials
Cheng, S. K., Dietrich, M. S., & Dilts, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1730 · Cited by 53 · cited 1×
“Oncology trials were examined on 10 dimensions: (1) number of arms, (2) masking, (3) randomization, (4) phase, (5) comparator arms, (6) purpose of intervention, (7) enrollment status, (8) location of trial sites, (9) sponsor, and (10) completion status.”
BackgroundSelf-citationStrengthening clinical cancer research in the United Kingdom
Stead, M. L., Cameron, D., Lester, N., Parmar, M., Haward, R., Kaplan, R. S., Maughan, T., Wilson, R. G., Campbell, H., Hamilton, R., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.69 · Cited by 42
Landscape of cancer clinical trials in Australia: using trial registries to guide future research
Dear, R. F.-G., Barratt, A. L., McGeechan, K., Askie, L. M., Simes, J. R., & Tattersall, M. H. N. (2011) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2011.tb03027.x · Cited by 22
Data mining of cancer vaccine trials: a bird's-eye view
Cao, X., Maloney, K. B., & Brusić, V. (2008) · Immunome Research · doi:10.1186/1745-7580-4-7 · Cited by 22
Kopetz, S., Overman, M. J., Chang, D. Z., Glover, K. Y., Shureiqi, I., Wolff, R. A., Abbruzzese, J. L., & Eng, C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2407 · Cited by 16
Accelerated Approval of Oncology Drugs: Can We Do Better?
Ellenberg, S. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr104 · Cited by 12 · cited 1×
“Oncology trials were examined on 10 dimensions: (1) number of arms, (2) masking, (3) randomization, (4) phase, (5) comparator arms, (6) purpose of intervention, (7) enrollment status, (8) location of trial sites, (9) sponsor, and (10) completion status.”
Background
Cited by
The COMET Handbook: version 1.0
Williamson, P. R., Altman, D. G., Bagley, H., Barnes, K. L., Blazeby, J. M., Brookes, S. T., Clarke, M., Gargon, E., Gorst, S., Harman, N., et al. (2017) · Trials · doi:10.1186/s13063-017-1978-4 · Cited by 2,011
“als found that more than 25,000 outcomes appeared only once or twice [15] and (2) in 102/143 (71%) Cochrane re-”
BackgroundUnger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M., & Fleury, M. E. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy221 · Cited by 570
Choosing Important Health Outcomes for Comparative Effectiveness Research: A Systematic Review
Gargon, E., Gurung, B., Medley, N., Altman, D. G., Blazeby, J. M., Clarke, M., & Williamson, P. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099111 · Cited by 337
The use of qualitative methods to inform Delphi surveys in core outcome set development
Keeley, T., Williamson, P., Callery, P., Jones, L. L., Mathers, J., Jones, J., Young, B., & Calvert, M. (2016) · Trials · doi:10.1186/s13063-016-1356-7 · Cited by 174
“gov database [6].”
Adult cancer clinical trials that fail to complete: an epidemic?
Stensland, K. D., McBride, R. B., Latif, A., Wisnivesky, J., Hendricks, R., Roper, N., Boffetta, P., Hall, S. J., Oh, W. K., & Galsky, M. D. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju229 · Cited by 161
Metadata
- Authors
- Hirsch, B. R., Califf, R. M., Cheng, S. K., Tasneem, A., Horton, J., Chiswell, K., Schulman, K. A., Dilts, D. M., & Abernethy, A. P.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-10
- Volume
- 173
- Issue
- 11
- Pages
- 972
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2087351488
- Cited by
- 183
- References
- 31
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.